Goldman Sachs analyst Richard Law raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $29 from $19 and keeps a Neutral rating on the shares. Arcutis announced Q3 results and hosted an Investor Day to present more information on its three growth pillars that could potentially drive Zoryve’s peak sales to $2.6B-$3.5B per annum, the analyst tells investors in a research note. Goldman’s updated model assumes sustained growth without the need for future capital raises.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
- Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
- Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
- Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat